NASDAQ:AVXL Anavex Life Sciences (AVXL) Stock Price, News & Analysis → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free AVXL Stock Alerts $3.80 -0.08 (-2.06%) (As of 03:09 PM ET) Add Compare Share Share Today's Range$3.75▼$3.9250-Day Range$3.39▼$5.4552-Week Range$3.25▼$10.45Volume560,593 shsAverage Volume1.38 million shsMarket Capitalization$312.03 millionP/E RatioN/ADividend YieldN/APrice Target$40.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Anavex Life Sciences alerts: Email Address Anavex Life Sciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside925.6% Upside$40.00 Price TargetShort InterestBearish25.93% of Shares Sold ShortDividend StrengthN/ASustainability-0.83Upright™ Environmental ScoreNews Sentiment0.06Based on 20 Articles This WeekInsider TradingSelling Shares$374,972 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.57) to ($0.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.46 out of 5 starsMedical Sector285th out of 915 stocksBiological Products, Except Diagnostic Industry35th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingAnavex Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAnavex Life Sciences has only been the subject of 1 research reports in the past 90 days.Read more about Anavex Life Sciences' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted25.93% of the outstanding shares of Anavex Life Sciences have been sold short.Short Interest Ratio / Days to CoverAnavex Life Sciences has a short interest ratio ("days to cover") of 16.6, which indicates bearish sentiment.Change versus previous monthShort interest in Anavex Life Sciences has recently decreased by 3.27%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAnavex Life Sciences does not currently pay a dividend.Dividend GrowthAnavex Life Sciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAnavex Life Sciences has received a 73.63% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for genetic diseases", "Preclinical research services for mental health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Anavex Life Sciences is -0.83. Previous Next 1.7 News and Social Media Coverage News SentimentAnavex Life Sciences has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Anavex Life Sciences this week, compared to 3 articles on an average week.Search InterestOnly 13 people have searched for AVXL on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Anavex Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anavex Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $374,972.00 in company stock.Percentage Held by Insiders11.60% of the stock of Anavex Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.55% of the stock of Anavex Life Sciences is held by institutions.Read more about Anavex Life Sciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Anavex Life Sciences are expected to decrease in the coming year, from ($0.57) to ($0.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anavex Life Sciences is -7.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anavex Life Sciences is -7.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnavex Life Sciences has a P/B Ratio of 2.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Anavex Life Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingREAD THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”Click on Adam's shiny forehead for more details. About Anavex Life Sciences Stock (NASDAQ:AVXL)Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Read More AVXL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVXL Stock News HeadlinesMay 10, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Anavex Life Sciences Corp. (AVXL)May 10, 2024 | finance.yahoo.comAnavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2024 Earnings Call TranscriptMay 10, 2024 | Banyan Hill Publishing (Ad)READ THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”May 10, 2024 | prnewswire.comShareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn MoreMay 9, 2024 | markets.businessinsider.comBuy Rating on Anavex Life Sciences Amid Promising Alzheimer’s Drug ProspectsMay 9, 2024 | markets.businessinsider.comAVXL Stock Earnings: Anavex Life Sciences Misses EPS for Q2 2024May 9, 2024 | uk.finance.yahoo.comAnavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business UpdateMay 9, 2024 | finanznachrichten.deAnavex Life Sciences Corp.: Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business UpdateMay 10, 2024 | Banyan Hill Publishing (Ad)READ THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”May 9, 2024 | globenewswire.comAnavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business UpdateMay 8, 2024 | prnewswire.comBERGER MONTAGUE PC ANNOUNCES THE FILING OF A CLASS ACTION COMPLAINT TO RECOVER LOSSES FOR INVESTORS WHO PURCHASED ANAVEX LIFE SCIENCES CORPORATION (NASDAQ: AVXL)May 8, 2024 | americanbankingnews.comAnavex Life Sciences (AVXL) Scheduled to Post Quarterly Earnings on ThursdayMay 8, 2024 | prnewswire.comLevi & Korsinsky Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline - AVXLMay 7, 2024 | prnewswire.comSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses of $100,000 to Contact the FirmMay 7, 2024 | prnewswire.comThe Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) ShareholdersMay 6, 2024 | prnewswire.comAVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud LawsuitMay 6, 2024 | prnewswire.comShareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreMay 5, 2024 | stockhouse.comIMMINENT AVXL DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Anavex Life Sciences Corp. Investors to Join the Class Action Lawsuit!May 5, 2024 | markets.businessinsider.comONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Anavex Life SciencesMay 5, 2024 | markets.businessinsider.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Anavex Life SciencesMay 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AnavexMay 3, 2024 | prnewswire.comAnavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXLMay 2, 2024 | prnewswire.comAVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud LawsuitMay 2, 2024 | markets.businessinsider.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Anavex Life SciencesMay 2, 2024 | globenewswire.comAnavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024May 1, 2024 | prnewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Corporation Lawsuit - AVXLApril 29, 2024 | prnewswire.comAVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud LawsuitSee More Headlines Receive AVXL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anavex Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/27/2023Today5/10/2024Next Earnings (Estimated)8/13/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:AVXL CUSIPN/A CIK1314052 Webwww.anavex.com Phone(844) 689-3939FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$40.00 High Stock Price Target$40.00 Low Stock Price Target$40.00 Potential Upside/Downside+930.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,510,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-30.32% Return on Assets-27.87% Debt Debt-to-Equity RatioN/A Current Ratio11.85 Quick Ratio11.85 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.73 per share Price / Book2.24Miscellaneous Outstanding Shares82,113,000Free Float72,588,000Market Cap$318.60 million OptionableOptionable Beta0.66 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Christopher U. Missling M.B.A. (Age 58)M.S., Ph.D., President, CEO, Secretary & Director Comp: $828.25kMs. Sandra Boenisch CPA (Age 43)CGA, Principal Financial Officer & Treasurer Comp: $194.36kMr. Stephan Toutain M.B.A. (Age 58)M.S., Senior VP of Operations & COO Dr. Walter E. Kaufmann M.D.Chief Scientific OfficerClint TomlinsonVP of CorporateDr. Adebayo Laniyonu Ph.D.Senior Vice President of Nonclinical DevelopmentDr. Edward R Hammond M.D.M.P.H., Ph.D., Chief Medical OfficerDr. Kun Jin Ph.D.Head of BiostatisticsMr. David Goldberger R.Ph.Senior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsSOPHiA GENETICSNASDAQ:SOPHInvivydNASDAQ:IVVDCaribou BiosciencesNASDAQ:CRBUJasper TherapeuticsNASDAQ:JSPRMonte Rosa TherapeuticsNASDAQ:GLUEView All CompetitorsInsiders & InstitutionsNwam LLCBought 38,437 shares on 5/10/2024Ownership: 1.019%Jupiter Asset Management Ltd.Bought 700,812 shares on 5/10/2024Ownership: 0.980%Geneos Wealth Management Inc.Bought 6,800 shares on 5/4/2024Ownership: 0.091%Mirae Asset Global Investments Co. Ltd.Bought 12,728 shares on 5/1/2024Ownership: 0.067%BNP Paribas Financial MarketsSold 64,505 shares on 5/1/2024Ownership: 0.057%View All Insider TransactionsView All Institutional Transactions AVXL Stock Analysis - Frequently Asked Questions Should I buy or sell Anavex Life Sciences stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anavex Life Sciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AVXL shares. View AVXL analyst ratings or view top-rated stocks. What is Anavex Life Sciences' stock price target for 2024? 1 brokerages have issued 12-month price objectives for Anavex Life Sciences' shares. Their AVXL share price targets range from $40.00 to $40.00. On average, they predict the company's stock price to reach $40.00 in the next twelve months. This suggests a possible upside of 925.6% from the stock's current price. View analysts price targets for AVXL or view top-rated stocks among Wall Street analysts. How have AVXL shares performed in 2024? Anavex Life Sciences' stock was trading at $9.31 at the beginning of the year. Since then, AVXL shares have decreased by 58.1% and is now trading at $3.90. View the best growth stocks for 2024 here. When is Anavex Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our AVXL earnings forecast. How were Anavex Life Sciences' earnings last quarter? Anavex Life Sciences Corp. (NASDAQ:AVXL) released its earnings results on Thursday, May, 9th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.13). During the same quarter last year, the company earned ($0.17) earnings per share. What ETF holds Anavex Life Sciences' stock? iShares Neuroscience and Healthcare ETF holds 5,746 shares of AVXL stock, representing 0.61% of its portfolio. What other stocks do shareholders of Anavex Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Anavex Life Sciences investors own include Inovio Pharmaceuticals (INO), POET Technologies (POETF), Brainstorm Cell Therapeutics (BCLI), LadRx (CYTR), SharkNinja (SN), Novavax (NVAX), Geron (GERN), VASCO Data Security International (VDSI), Sorrento Therapeutics (SRNE) and OPKO Health (OPK). Who are Anavex Life Sciences' major shareholders? Anavex Life Sciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Nwam LLC (1.02%), Jupiter Asset Management Ltd. (0.98%), Los Angeles Capital Management LLC (0.11%), Geneos Wealth Management Inc. (0.09%), Mirae Asset Global Investments Co. Ltd. (0.07%) and BNP Paribas Financial Markets (0.06%). Insiders that own company stock include Athanasios Skarpelos, Christopher U Missling, Elliot Favus, Elliot Favus, Peter DO Donhauser and Sandra Boenisch. View institutional ownership trends. How do I buy shares of Anavex Life Sciences? Shares of AVXL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AVXL) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis 1 Biotech Stock has been shocking the marketsHuge AlertsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anavex Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
